HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low molecular weight compounds with affinity to melanocortin receptors exert neuroprotection in spinal cord injury--an experimental study in the rat.

Abstract
The possibility that five new low molecular weight compounds with varying affinity and selectivity to the melanocortin receptors will exert neuroprotective effects in the spinal cord injury (SCI) induced edema formation and cell damage was examined in a rat model. A focal trauma of the rat spinal cord made by an incision into the right dorsal horn (T10-11) resulted in profound edema formation, leakage of Evans blue albumin and cell injury of the T9 segment at 5 h. Topical application of the Melacure compound ME10501 in high doses (10 microg in 10 microl) given 5 min after SCI resulted in most significant neuroprotection of the T9 segment of the cord compared to other compounds. Thus, marked reduction in water content, leakage of Evans blue albumin, and cell injury were observed in ME10501 treated traumatised rats. These observations suggest that the non-peptide compound ME10501 with affinity to the melanocortin receptor MC4 is capable to induce neuroprotection in the spinal cord following trauma not reported earlier.
AuthorsH S Sharma, T Lundstedt, M Flärdh, J Westman, C Post, A Skottner
JournalActa neurochirurgica. Supplement (Acta Neurochir Suppl) Vol. 86 Pg. 399-405 ( 2003) ISSN: 0065-1419 [Print] Austria
PMID14753476 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Neuroprotective Agents
  • Receptors, Melanocortin
Topics
  • Animals
  • Binding, Competitive
  • Body Water (metabolism)
  • Capillary Permeability (drug effects)
  • Edema (etiology)
  • Male
  • Molecular Weight
  • Neuroprotective Agents (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Melanocortin (metabolism)
  • Spinal Cord (blood supply, drug effects, pathology, physiopathology)
  • Spinal Cord Diseases (etiology)
  • Spinal Cord Injuries (complications, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: